Tecomet and Orchid Orthopedic Solutions announced that they began an agreement to merge, combining complementary capabilities to better serve customers, expand reach, and support long-term growth.

Tecomet is a designer, developer, and manufacturer of medtech as well as aerospace and defense products. Orchid offers solutions for procedures in major medtech markets in the U.S. and Europe.

The combined company will provide a portfolio of medtech solutions with a broader, more resilient manufacturing footprint and more capacity to invest in advanced manufacturing, automation, and capacity expansion. They share the goal of serving customers to the highest standard and have the joint support of both Charlesbank Capital Partners and Nordic Capital, who have been the majority owners of Tecomet and Orchid since 2017 and 2019, respectively.

“We are not just merging two companies—we are committed to an integration that builds on the strengths and heritage of both Tecomet and Orchid,” said Tecomet president and CEO Andreas S. Weller. “With complementary technologies, expanded reach and a dedicated workforce across six countries, we believe the combined company will be better positioned to advance innovation and deliver reliable, high-quality solutions for surgeons worldwide.”

Until the transaction is complete, Tecomet and Orchid will operate as separate companies. The merger is subject to regulatory approvals and other closing conditions.

“Strategically, this is a strong fit. By combining our manufacturing capabilities, technical expertise and global footprints, we’re creating a stronger, more competitive organization,” said Orchid CEO Nate Folkert. “Just as importantly, this combination is about long-term stability—building a company that is well equipped to grow, invest and create opportunity for our people.”